SCHEDULE: Johnson & Johnson Amends SEC Filing for Rallybio Stake

Johnson & Johnson and its subsidiary JJDC have amended their Schedule 13G filing, reporting a combined beneficial ownership of 2.9% in Rallybio Corporation as of March 31, 2026.

Summary

• Johnson & Johnson (J&J) and its wholly-owned subsidiary, Johnson & Johnson Innovation - JJDC, Inc. (JJDC), have filed an amendment (Amendment No. 1) to their Schedule 13G filing.
• This filing pertains to their beneficial ownership of common stock in Rallybio Corporation.
• As of March 31, 2026, JJDC directly beneficially owns 152,901 shares of Rallybio's common stock.
• J&J may be deemed to indirectly beneficially own these same securities.
• The combined beneficial ownership represents 2.9% of Rallybio Corporation's common stock.
• This percentage is based on 5,289,675 shares of common stock outstanding as of March 6, 2026, as reported in Rallybio's Form 10-K for the period ended December 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine amendment to a Schedule 13G reporting passive ownership and does not contain new strategic information or performance data.

Positives

• Johnson & Johnson and JJDC maintain a significant, albeit passive, stake in Rallybio Corporation, indicating continued interest or investment.
• The filing confirms a stable ownership percentage of 2.9%, suggesting no significant recent changes in their holdings.

Negatives

• The filing does not disclose any new strategic initiatives or increased investment from Johnson & Johnson in Rallybio, beyond the reported passive stake.

Risks

• The filing does not explicitly mention any risks associated with Rallybio Corporation. The primary risk for J&J and JJDC would be the potential decline in the value of their investment in Rallybio.

Future Outlook

The filing is an amendment to a Schedule 13G and does not contain forward-looking statements or guidance from Rallybio Corporation. It solely reports on the beneficial ownership of Johnson & Johnson and JJDC.

Industry Context

StockSavvy.ai notes that this Schedule 13G amendment by Johnson & Johnson and JJDC indicates a passive investment in Rallybio Corporation. Such filings are common for large corporations holding stakes in smaller, potentially innovative biotech firms, often as part of their venture capital or strategic investment arms.

Stakeholder Impact

• Shareholders of Rallybio Corporation: The filing confirms a stable, passive ownership stake by a major healthcare conglomerate, which can be viewed positively for stability but does not indicate active support or control.
• Johnson & Johnson Shareholders: The investment represents a small portion of J&J's overall portfolio, with minimal direct impact unless Rallybio's performance significantly deviates from expectations.

Next Steps

• Johnson & Johnson and JJDC will continue to monitor their investment in Rallybio Corporation.
• Rallybio Corporation will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Keywords

Rallybio Corporation, Johnson & Johnson, JJDC, Schedule 13G, SEC Filing, Beneficial Ownership, Common Stock, Amendment, Investment